Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Lineage Cell Therapeutics (LCTX) Accumulated Depreciation & Amortization (2016 - 2026)

Lineage Cell Therapeutics has reported Accumulated Depreciation & Amortization over the past 16 years, most recently at $327000.0 for Q1 2026.

  • For Q1 2026, Accumulated Depreciation & Amortization fell 83.72% year-over-year to $327000.0; the TTM value through Mar 2026 reached $327000.0, down 83.72%, while the annual FY2025 figure was $2.7 million, 232.58% up from the prior year.
  • Accumulated Depreciation & Amortization for Q1 2026 was $327000.0 at Lineage Cell Therapeutics, down from $2.7 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $441.0 million in Q3 2022 and troughed at -$2.0 million in Q4 2024.
  • A 5-year average of $68.2 million and a median of $582000.0 in 2022 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 267172.73% in 2022 and later tumbled 3110.29% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $582000.0 in 2022, then tumbled by 88.32% to $68000.0 in 2023, then tumbled by 3110.29% to -$2.0 million in 2024, then skyrocketed by 232.58% to $2.7 million in 2025, then crashed by 87.95% to $327000.0 in 2026.
  • Business Quant data shows Accumulated Depreciation & Amortization for LCTX at $327000.0 in Q1 2026, $2.7 million in Q4 2025, and $385000.0 in Q3 2025.